Mechanism of Action of Ranolazine

Primary Mechanism of Action

• Ranolazine primarily works through concentration-dependent, voltage-dependent, and frequency-dependent inhibition of the late sodium current (late INa), which prevents intracellular calcium overload during ischemia, according to the American College of Cardiology 1
• The American Heart Association recommends ranolazine for its antianginal effects, which are contributed by its dual mechanism of action, including inhibition of late sodium current and metabolic effects, such as promoting glucose oxidation and improving anaerobic metabolism under ischemic conditions 1

Physiological Effects

• The European Society of Cardiology notes that ranolazine decreases sodium-dependent intracellular calcium accumulation during ischemia, leading to reduced oxygen demand and left ventricular wall tension 1

Clinical Effects

• The American College of Cardiology states that ranolazine exerts antianginal effects without significantly affecting heart rate, blood pressure, or myocardial perfusion, with minimal changes in these parameters 1

Important Clinical Considerations

• The American Heart Association warns that ranolazine causes dose-related QT interval prolongation, though torsades de pointes has not been observed at therapeutic doses, and recommends caution in patients with hepatic impairment or liver cirrhosis 1
• The European Society of Cardiology advises that ranolazine is contraindicated in patients with hepatic impairment or liver cirrhosis, and recommends caution when co-administered with strong CYP3A inhibitors or digoxin 1
• The American Diabetes Association notes that ranolazine reduces glycated hemoglobin (HbA1c) levels in diabetic patients, though it is not considered a treatment for diabetes 1

Ranolazine Therapy for Chronic Angina

Patient Populations and Efficacy

• Patients with diabetes and chronic stable angina may benefit from ranolazine treatment, as it reduces glycated hemoglobin levels, according to the Nature Reviews Cardiology 2
• Patients with left ventricular hypertrophy might experience greater efficacy with ranolazine compared to other antianginal drugs, as noted by the Nature Reviews Cardiology 2
• Ranolazine may be useful in cases of bradycardia and/or hypotension due to its neutral hemodynamic profile, as reported by the Nature Reviews Cardiology 2

Contraindications and Precautions

• Ranolazine is contraindicated in patients with hepatic impairment or liver cirrhosis, according to the Nature Reviews Cardiology 2

Clinical Outcomes

• Ranolazine does not improve outcomes in patients with chronic stable angina, regardless of ventricular function, as stated by the Nature Reviews Cardiology 2
• It has not been shown to reduce major cardiovascular events, including cardiovascular death and myocardial infarction, in patients with non-ST-segment elevation acute coronary syndrome, according to the Nature Reviews Cardiology 2

Ranolazine for Chronic Angina Pectoris

Introduction to Ranolazine

• The American Heart Association recommends ranolazine at an initial dose of 500 mg orally twice daily, which can be escalated as needed to a maximum of 1000 mg twice daily for the treatment of chronic angina that has failed to respond to standard antianginal therapy 3
• Ranolazine exerts its effects without significantly reducing heart rate or blood pressure, making it particularly useful in patients with bradycardia or hypotension 3

Indications and Usage

• Ranolazine is indicated for the treatment of chronic angina pectoris as monotherapy or in combination with amlodipine, beta-blockers, or nitrates when angina is not adequately controlled with standard therapy 3

Clinical Outcomes and Limitations

• In a large trial of patients with unstable angina or non-ST-elevation myocardial infarction, ranolazine provided symptom relief but did not significantly reduce the composite of cardiovascular death, myocardial infarction, or recurrent ischemia 3
• Ranolazine is contraindicated in patients with hepatic impairment or liver cirrhosis 3

Ranolazine for Chronic Angina Management

Indications and Place in Therapy

• The European Society of Cardiology recommends ranolazine as add-on therapy in patients with inadequate control of chronic angina symptoms while on treatment with beta-blockers and/or calcium channel blockers, or as part of initial treatment in properly selected patients (Class IIa, Level B recommendation) 4, 5
• Ranolazine can be considered as part of initial treatment in properly selected patients, according to the European Society of Cardiology guidelines 4, 5

Special Populations and Considerations

• Patients with diabetes and chronic stable angina may benefit from ranolazine treatment, as it has been shown to reduce glycated hemoglobin levels, according to the European Society of Cardiology 6
• Ranolazine may be particularly useful in cases of bradycardia and/or hypotension due to its neutral hemodynamic profile, as noted by the European Society of Cardiology 6

Contraindications and Precautions

• Ranolazine is contraindicated in patients with liver cirrhosis, as stated by the European Society of Cardiology 6
• Use of ranolazine with caution is recommended in patients taking digoxin, as ranolazine increases digoxin concentration, according to the European Society of Cardiology 6

Clinical Outcomes

• Ranolazine effectively reduces angina symptoms and improves exercise tolerance, but has not been shown to improve major cardiovascular outcomes or reduce mortality in patients with chronic stable angina, as reported by the European Society of Cardiology 6

Ranolazine Use in Chronic Angina

Special Populations and Clinical Considerations

• Ranolazine should be the preferred antianginal agent in patients with type 2 diabetes and chronic stable angina, as it significantly reduces glycated hemoglobin (HbA1c) levels, fasting glucose, and 2-hour postprandial glucose levels while simultaneously reducing angina pain and increasing exercise tolerance 7
• The European Society of Cardiology is not cited for any recommendations in this article, however, ranolazine can be added to beta-blockers in patients with both chronic stable angina and atrial fibrillation, as it has been shown to suppress supraventricular arrhythmias and atrial fibrillation 7
• Ranolazine can be added without concern for excessive blood pressure lowering in patients with hypertension 7
• Ranolazine undergoes extensive hepatic metabolism but is primarily excreted by the kidney, and plasma levels increase 50-97% as kidney function declines 7
• Plasma levels increase up to 50-60% in patients with moderate hepatic impairment 7
• Trimetazidine should also be avoided when GFR is <30 mL/min/1.73 m² 7

ESC Guideline Recommendations for Ranolazine in Chronic Stable Angina

Indications

• Ranolazine is recommended as a second‑line anti‑anginal agent for chronic stable angina when symptoms remain uncontrolled with beta‑blockers and/or calcium‑channel blockers, or when first‑line agents are not tolerated. (Class IIa, Level B) – European Society of Cardiology 8, 9, 10

Initial Pharmacologic Strategy

• Beta‑blockers and/or calcium‑channel blockers continue to be the preferred first‑line therapy for most patients with chronic coronary syndrome. (Class I, Level A) – European Society of Cardiology 8, 9

Add‑On Therapy (Ranolazine)

• Ranolazine should be added when initial beta‑blocker and/or calcium‑channel blocker therapy fails to adequately control angina symptoms. (Class IIa, Level B) – European Society of Cardiology 8, 9, 10

Substitute Therapy

• Ranolazine may replace beta‑blockers in patients who experience unacceptable side effects, have ineffective response, or have contraindications to beta‑blockers (e.g., bradycardia or hypotension). (Class IIb, Level C) – American College of Cardiology 11

Combination Therapy

• Combining ranolazine with beta‑blockers provides effective symptom relief in patients whose angina persists despite optimal beta‑blocker dosing. (Class IIa, Level A) – American College of Cardiology 11

Special Populations

Microvascular Angina

• In patients with microvascular angina, a regimen of ranolazine plus trimetazidine yields superior symptom control compared with monotherapy. (Class IIa, Level B) – European Society of Cardiology 8, 10

Contraindications

• Absolute contraindication: documented liver cirrhosis. – European Society of Cardiology 8, 9, 10

Drug‑Interaction Precautions

Digoxin

• Ranolazine increases digoxin plasma concentrations; dose adjustment of digoxin is required when the two drugs are co‑administered. – European Society of Cardiology 9

General Interaction Monitoring

• Clinicians should monitor for interactions with digoxin, statins, and metformin when prescribing ranolazine, adjusting doses of the co‑administered agents as needed. – European Society of Cardiology 9

All recommendations reflect the strength of evidence as reported in the cited guideline documents.